Researchers in Australia are conducting a trial to see whether squirting a blood thinner into the nose could offer protection against COVID-19, BBC News reported on Wednesday.
The nasal spray reportedly uses the economical drug heparin in an attempt to neutralise COVID-19's spike protein.
According to researchers, when sprayed into the nose of an infected person, it appears to make them non-infectious.
Researchers hope the spray could help both as an early treatment and as a nasal mask to stop the virus spreading, BBC added.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial